Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

  • In development
  • GID-TA11956
  • Expected publication date: 

Documents

Documents created during the development process.

Committee meetings

  • Committee meeting: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators